- Report
- August 2025
- 181 Pages
Global
From €3126EUR$3,545USD£2,722GBP
€3474EUR$3,939USD£3,024GBP
- Report
- October 2025
- 192 Pages
Global
From €3126EUR$3,545USD£2,722GBP
€3474EUR$3,939USD£3,024GBP
- Report
- October 2025
- 182 Pages
Global
From €3126EUR$3,545USD£2,722GBP
€3474EUR$3,939USD£3,024GBP
- Report
- September 2025
- 250 Pages
Global
From €3959EUR$4,490USD£3,447GBP
- Report
- May 2025
- 175 Pages
Global
From €3959EUR$4,490USD£3,447GBP
- Report
- October 2025
- 183 Pages
Global
From €5159EUR$5,850USD£4,492GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1323EUR$1,500USD£1,152GBP
- Report
- June 2025
- 400 Pages
Global
From €4364EUR$4,949USD£3,800GBP
- Report
- October 2025
- 50 Pages
Global
From €2337EUR$2,650USD£2,035GBP
- Report
- October 2025
- 50 Pages
Global
From €2337EUR$2,650USD£2,035GBP
Fosaprepitant is a drug used in the treatment of gastrointestinal disorders. It is a prodrug of aprepitant, a neurokinin-1 (NK-1) receptor antagonist, and is used to prevent nausea and vomiting caused by chemotherapy. Fosaprepitant is administered intravenously and is available in both single-dose and multiple-dose vials. It is typically used in combination with other antiemetic drugs, such as ondansetron and dexamethasone. Fosaprepitant has been shown to be effective in reducing the incidence of nausea and vomiting in patients receiving chemotherapy.
Fosaprepitant is marketed by several pharmaceutical companies, including Merck & Co., Inc., Teva Pharmaceuticals, and Sun Pharmaceutical Industries Ltd. It is also available as a generic drug in some countries. Show Less Read more